Hematology/Oncology and Outcomes Research, Saint Louis University and St. Louis Veterans Affairs Medical Center, prostate cancer-myeloma modeling/data science
Saint Louis, MO, USA
Joined June 2009
- Tweets787
- Following239
- Followers662
- Likes704
Martin Schoen MD MPH retweeted
Bytes to Bedside @mwschoen @VAResearch @PCFnews #PCFRetreat26 discusses his work STRATOS-P putting VA data to work for Veterans & PCF-VA Partnership
Martin Schoen MD MPH retweeted
The value of the VA and @PCF_Science collaboration shown by @mwschoen with a clinico-genomic classifier for men with metastatic prostate cancer
Martin Schoen MD MPH retweeted
Dr. Schoen’s @mwschoen VA-DOSE Bytes to Bedside - and decentralized trial design @VAResearch @PCFnews #PCFRetreat26 #pragmatictrials
Martin Schoen MD MPH retweeted
Just out!! In @NEJM - Our randomized trial in myeloma (ENDURANCE trial) shows limited duration of lenalidomide maintenance is just as good as indefinite therapy, with less side effects!!! @eaonc @theNCI
Implications are HUGE. This is a drug we spends billions on each year:
-Less side effects
-Less second cancers
-Similar overall survival
-Less cost
@myelomaMD @Myeloma_Doc @SagarLonialMD
National NCI funded trial led by @eaonc and joined by @ALLIANCE_org & @SWOG
nejm.org/doi/full/10.1056/NE…
Observational Study of U.S. Veterans With mCSPC Shows OS Benefit of ADT + ARPI in Patients Who Are Elderly, Frail, or Affected by Substantial Comorbidities dailynews.ascopubs.org/do/ob…
bit.ly/4qVMZam
3
3
152
Martin Schoen MD MPH retweeted
Ab#103 @ASCO #GU26 by @mwschoen👉bit.ly/4qVMZam👉Real-world cohort of elderly/frail veterans w/ de novo mHSPC receiving ADT +/- ARPIs #prostatecancer👉ARPI + ADT improved OS regardless of old age or frailty👇#MaelysTouya @OncoAlert @urotoday @PCF_Science
Martin Schoen MD MPH retweeted
Check our viewpoint published @JAMA_current #MedEd
Abstract Factory—Research Culture Harming Medical Education
The "abstract factory" is destroying medical education. Trainees and junior faculty compete with abstract counts instead of meaningful research. Result: inflated CVs, diluted conferences. We shouldn't celebrate this—you don't need publications to be a great doctor.
➡️jamanetwork.com/journals/jam…
@utswcancer @rajshekharucms @HiraSMian @ManniMD1 @HemOncFellows @ASCOTECAG
Martin Schoen MD MPH retweeted
The real question is what is the clinical importance of “new #PSMA+ PET lesions”
And if we are treating PSMA+ #BCR with ADT because we are conflating that disease state with #mCSPC, then I’m not quite sure how to factor in “delaying ADT” as a benefit.
#ProstateCancer @JCO_ASCO
🚀 LUNAR Trial
In oligorecurrent HSPC, adding 2 cycles of ¹⁷⁷Lu-PSMA before SBRT more than doubles PFS (7.4 → 17.6 months) — a 63% reduction in progression, without added toxicity.
🔬 98% of progressions were new PSMA PET lesions, underscoring the power of targeting micrometastatic disease early.
📌 Importantly, it also delays the need for ADT— a major quality-of-life win.
📈 A compelling signal heading toward Phase III validation
@OncoAlert @MedwatchKate @weoncologists @OncoReporte @TresUramigas @Uromigos
Martin Schoen MD MPH retweeted
Meet @mwschoen, VA St. Louis oncologist and 2022 Young Investigator Award recipient.
Using data from the VA, Dr. Schoen found that adding a newer hormone therapy to standard ADT helps men with advanced prostate cancer live longer.
Real-world data from @DeptVetAffairs helps to understand trends and inform practice. Survival in metastatic prostate cancer is increasing, likely due to use of androgen receptor pathway inhibitors. Now we show no difference in OS between abiraterone and enzalutamide @HarshrajL
ALT Survival is improving in metastatic prostate cancer over the last 20 years, especially in younger patients
ALT The use of ARPIs are increasing in metastatic prostate cancer, over 50% in 2021
ALT There is no difference in survival with abiraterone compared to enzalutamide
No difference in OS was not a surprise, the drugs have similar efficacy in trials and meta-analyses from @IrbazRiaz. We compared ARPIs vs. docetaxel for mHSPC in jamanetwork.com/journals/jam… and found no difference in OS, just real-world PFS, showing effect of subsequent therapy on OS
ALT No difference in OS between ARPIs and docetaxel in mHSPC. There was longer real world progression-free survival with ARPIs.
1
3
216
Thanks to @PCF_Science @PCFnews @urotoday for supporting these series of papers in @JAMANetworkOpen. More to come on triple therapy and use of tumor genomics to guide therapy supported by @VAResearch at @VASTLResearch with @slusom students and @SLU_Official @SLUHealthNews
1
102
Martin Schoen MD MPH retweeted
Antonio “Tito” Fojo, MD, PhD, discussed a new metric called “g” for tumor growth that correlates with survival. His team has developed an online tool for providers in the VA to help guide treatment choice and optimize care of Veterans with #prostatecancer. #PCFRetreat25
Martin Schoen MD MPH retweeted
Comprehensive discussion about targeting HRR alterations with PARP inhibitors in metastatic prostate cancer by @neerajaiims #ESMO25
Martin Schoen MD MPH retweeted
Also, improving PFS doesn’t automatically mean QOL has improved.
onlinelibrary.wiley.com/doi/…
jamanetwork.com/journals/jam…
